Clovis Oncology, Inc. NASDAQ:CLVS

Founder-led company

Clovis Oncology stock price today

$0.081
-0.03
-32.33%
Financial Health
0
1
2
3
4
5
6
7
8
9

Clovis Oncology stock price monthly change

+99.67%
month

Clovis Oncology stock price quarterly change

-87.43%
quarter

Clovis Oncology stock price yearly change

-93.72%
year

Clovis Oncology key metrics

Market Cap
N/A
Enterprise value
411.98M
P/E
-0.03
EV/Sales
4.02
EV/EBITDA
-1.97
Price/Sales
0.11
Price/Book
-0.02
PEG ratio
N/A
EPS
-1.86
Revenue
103.70M
EBITDA
-209.12M
Income
-251.90M
Revenue Q/Q
-96.45%
Revenue Y/Y
-33.56%
Profit margin
-246.1%
Oper. margin
-225.56%
Gross margin
65.2%
EBIT margin
-225.56%
EBITDA margin
-201.66%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Clovis Oncology stock price history

Clovis Oncology stock forecast

Clovis Oncology financial statements

Clovis Oncology, Inc. (NASDAQ:CLVS): Profit margin
Dec 2021 35.96M -64.39M -179.02%
Mar 2022 34.24M -60.16M -175.69%
Jun 2022 32.14M -71.33M -221.92%
Sep 2022 1.34M -56.01M -4170.81%
Clovis Oncology, Inc. (NASDAQ:CLVS): Earnings per share (EPS)
2022-05-04 -0.43 -0.44
2022-08-08 -0.41 -0.5
2022-11-09 -0.41 -0.39
Clovis Oncology, Inc. (NASDAQ:CLVS): Debt to assets
Dec 2021 472833000 751.67M 158.97%
Mar 2022 451529000 754.83M 167.17%
Jun 2022 392856000 760.55M 193.6%
Sep 2022 346775000 764.66M 220.51%
Clovis Oncology, Inc. (NASDAQ:CLVS): Cash Flow
Dec 2021 -41.34M -69K 13.16M
Mar 2022 -58.49M -62K 37.85M
Jun 2022 -35.12M -46K 9.14M
Sep 2022 -40.61M -89K 6.17M

Clovis Oncology alternative data

Clovis Oncology, Inc. (NASDAQ:CLVS): Employee count
Aug 2023 413
Sep 2023 413
Oct 2023 413
Nov 2023 413
Dec 2023 413
Jan 2024 413
Feb 2024 413
Mar 2024 413
Apr 2024 413
May 2024 413
Jun 2024 413
Jul 2024 413

Clovis Oncology other data

43.58% -10.48%
of CLVS is owned by hedge funds
55.98M -9.54M
shares is hold by hedge funds

Clovis Oncology, Inc. (NASDAQ:CLVS): Insider trades (number of shares)
Period Buy Sel
Nov 2021 0 18695
Dec 2021 0 1294
Jan 2022 0 7
Feb 2022 0 21946
Mar 2022 0 50953
Apr 2022 0 7
May 2022 0 18901
Jun 2022 0 11429
Jul 2022 0 7
Aug 2022 0 19402
Sep 2022 0 10937
Oct 2022 0 6
Transaction Date Insider Security Shares Price per share Total value Source
Sale
HARDING THOMAS C. officer: Senior Vice President ..
Common Stock 6 $1.29 $8
Option
HARDING THOMAS C. officer: Senior Vice President ..
Restricted Stock Units 15 N/A N/A
Option
HARDING THOMAS C. officer: Senior Vice President ..
Common Stock 15 N/A N/A
Sale
MUEHL DANIEL W officer: Executiv.. Common Stock 2,234 $1.2 $2,681
Sale
IVERS-READ GILLIAN C officer: Executiv.. Common Stock 2,234 $1.2 $2,681
Sale
GROSS PAUL EDWARD officer: Executiv.. Common Stock 2,308 $1.2 $2,770
Sale
HARDING THOMAS C. officer: Executive Vice Preside..
Common Stock 172 $1.2 $206
Sale
HARDING THOMAS C. officer: Executive Vice Preside..
Common Stock 1,444 $1.2 $1,733
Sale
ROLFE LINDSEY officer: Chief Medical Officer ..
Common Stock 2,545 $1.2 $3,054
Option
MUEHL DANIEL W officer: Executiv.. Restricted Stock Units 5,063 N/A N/A
Monday, 14 August 2023
investorplace.com
Wednesday, 21 December 2022
Zacks Investment Research
Monday, 12 December 2022
WSJ
Zacks Investment Research
InvestorPlace
Market Watch
Monday, 5 December 2022
InvestorPlace
Friday, 25 November 2022
Zacks Investment Research
Monday, 21 November 2022
Zacks Investment Research
Friday, 18 November 2022
InvestorPlace
Tuesday, 15 November 2022
PennyStocks
Monday, 14 November 2022
InvestorPlace
Thursday, 10 November 2022
Zacks Investment Research
Wednesday, 9 November 2022
InvestorPlace
Market Watch
Saturday, 29 October 2022
Seeking Alpha
Monday, 3 October 2022
InvestorPlace
Wednesday, 21 September 2022
InvestorPlace
Wednesday, 14 September 2022
Zacks Investment Research
Tuesday, 13 September 2022
InvestorPlace
Monday, 12 September 2022
The Motley Fool
PennyStocks
InvestorPlace
Wednesday, 7 September 2022
Zacks Investment Research
Monday, 8 August 2022
Zacks Investment Research
The Motley Fool
InvestorPlace
Seeking Alpha
Monday, 1 August 2022
InvestorPlace
Wednesday, 20 July 2022
Business Wire
  • What's the price of Clovis Oncology stock today?

    One share of Clovis Oncology stock can currently be purchased for approximately $0.08.

  • When is Clovis Oncology's next earnings date?

    Unfortunately, Clovis Oncology's (CLVS) next earnings date is currently unknown.

  • Does Clovis Oncology pay dividends?

    No, Clovis Oncology does not pay dividends.

  • What is Clovis Oncology's stock symbol?

    Clovis Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CLVS".

  • What is Clovis Oncology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Clovis Oncology?

    Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Clovis Oncology's key executives?

    Clovis Oncology's management team includes the following people:

    • Mr. Patrick J. Mahaffy Co-Founder, Chief Executive Officer, Pres & Executive Director(age: 62, pay: $1,230,000)
    • Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer(age: 57, pay: $773,080)
    • Dr. Gillian C. Ivers-Read Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations(age: 71, pay: $741,940)
    • Mr. Paul Edward Gross Executive Vice President, Gen. Counsel & Sec.(age: 60, pay: $726,150)
    • Mr. Daniel W. Muehl Executive Vice President & Chief Financial Officer(age: 61, pay: $719,980)
  • Is Clovis Oncology founder-led company?

    Yes, Clovis Oncology is a company led by its founders Mr. Patrick J. Mahaffy and Dr. Gillian C. Ivers-Read.

  • How many employees does Clovis Oncology have?

    As Jul 2024, Clovis Oncology employs 413 workers.

  • When Clovis Oncology went public?

    Clovis Oncology, Inc. is publicly traded company for more then 13 years since IPO on 16 Nov 2011.

  • What is Clovis Oncology's official website?

    The official website for Clovis Oncology is clovisoncology.com.

  • Where are Clovis Oncology's headquarters?

    Clovis Oncology is headquartered at 5500 Flatiron Pkwy Unit 100, Boulder, COLORADO.

  • How can i contact Clovis Oncology?

    Clovis Oncology's mailing address is 5500 Flatiron Pkwy Unit 100, Boulder, COLORADO and company can be reached via phone at +1 303 625 5000.

Clovis Oncology company profile:

Clovis Oncology, Inc.

clovisoncology.com
Exchange:

NASDAQ

Full time employees:

413

Industry:

Biotechnology

Sector:

Healthcare

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

5500 Flatiron Pkwy Unit 100
Boulder, COLORADO 80301

CIK: 0001466301
ISIN: US1894641000
CUSIP: 189464100